OrbiMed’s Vertex Pharmaceuticals VRTX Stock Holding History

OrbiMed’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-210,287	Closed	-$93.6M	–	125
2025 Q2	$93.6M	Buy	210,287 +50,387	+32%	+$23.2M	2.34%	14
2025 Q1	$77.5M	Buy	159,900 +8,900	+6%	+$4.15M	1.85%	16
2024 Q4	$60.8M	Hold	151,000	–	–	1.25%	26
2024 Q3	$70.2M	Hold	151,000	–	–	1.28%	24
2024 Q2	$70.8M	Buy	151,000 +28,300	+23%	+$12.3M	1.4%	21
2024 Q1	$51.3M	Sell	122,700 -52,500	-30%	-$22.2M	0.94%	38
2023 Q4	$71.3M	Buy	175,200 +9,800	+6%	+$3.62M	1.42%	25
2023 Q3	$57.5M	Hold	165,400	–	–	1.22%	28
2023 Q2	$58.2M	Sell	165,400 -12,200	-7%	-$4.11M	1.05%	37
2023 Q1	$56M	Sell	177,600 -93,900	-35%	-$28.2M	1.1%	30
2022 Q4	$78.4M	Sell	271,500 -101,700	-27%	-$31M	1.5%	20
2022 Q3	$108M	Sell	373,200 -14,000	-4%	-$4.03M	2.01%	11
2022 Q2	$109M	Sell	387,200 -13,000	-3%	-$3.48M	1.98%	14
2022 Q1	$104M	Sell	400,200 -257,900	-39%	-$61.2M	1.69%	20
2021 Q4	$145M	Sell	658,100 -219,300	-25%	-$42.6M	1.86%	13
2021 Q3	$159M	Sell	877,400 -188,000	-18%	-$36.7M	1.75%	14
2021 Q2	$215M	Sell	1,065,400 -70,500	-6%	-$14.7M	2.17%	12
2021 Q1	$244M	Buy	1,135,900 +301,800	+36%	+$66.3M	2.28%	11
2020 Q4	$197M	Buy	834,100 +168,000	+25%	+$38.5M	1.73%	15
2020 Q3	$181M	Hold	666,100	–	–	2.28%	13
2020 Q2	$193M	Sell	666,100 -71,300	-10%	-$19.3M	2.72%	7
2020 Q1	$175M	Sell	737,400 -45,700	-6%	-$10.5M	2.95%	7
2019 Q4	$171M	Sell	783,100 -63,300	-7%	-$12.8M	2.45%	11
2019 Q3	$143M	Sell	846,400 -126,900	-13%	-$22.4M	2.72%	9
2019 Q2	$178M	Buy	973,300 +18,000	+2%	+$3.15M	2.76%	8
2019 Q1	$176M	Sell	955,300 -177,900	-16%	-$32.9M	2.72%	8
2018 Q4	$188M	Sell	1,133,200 -467,300	-29%	-$81M	3.47%	8
2018 Q3	$308M	Sell	1,600,500 -192,100	-11%	-$34.2M	3.72%	4
2018 Q2	$305M	Sell	1,792,600 -62,000	-3%	-$9.61M	3.63%	5
2018 Q1	$302M	Buy	1,854,600 +113,300	+7%	+$18.5M	3.75%	3
2017 Q4	$261M	Sell	1,741,300 -333,002	-16%	-$49.3M	3.3%	5
2017 Q3	$315M	Buy	2,074,302 +47,800	+2%	+$7.19M	3.01%	6
2017 Q2	$261M	Sell	2,026,502 -142,698	-7%	-$17.2M	2.74%	6
2017 Q1	$237M	Buy	2,169,200 +9,800	+0.5%	+$863K	2.69%	9
2016 Q4	$159M	Buy	2,159,400 +547,400	+34%	+$44.5M	2.03%	16
2016 Q3	$141M	Sell	1,612,000 -577,300	-26%	-$54.6M	1.6%	22
2016 Q2	$188M	Buy	2,189,300 +319,900	+17%	+$27.6M	1.97%	14
2016 Q1	$149M	Buy	1,869,400 +1,196,400	+178%	+$108M	1.56%	19
2015 Q4	$84.7M	Buy	673,000 +558,000	+485%	+$67.4M	0.77%	40
2015 Q3	$12M	Hold	115,000	–	–	0.12%	88
2015 Q2	$14.2M	Sell	115,000 -20,000	-15%	-$2.52M	0.12%	93
2015 Q1	$15.9M	Sell	135,000 -1,596,200	-92%	-$191M	0.14%	87
2014 Q4	$206M	Buy	1,731,200 +381,200	+28%	+$42.9M	1.97%	18
2014 Q3	$152M	Buy	1,350,000 +822,000	+156%	+$78.3M	1.58%	26
2014 Q2	$50M	Buy	528,000 +368,000	+230%	+$25.8M	0.59%	45
2014 Q1	$11.3M	Sell	160,000 -95,000	-37%	-$7.52M	0.14%	86
2013 Q4	$18.9M	Sell	255,000 -83,000	-25%	-$5.78M	0.28%	65
2013 Q3	$25.6M	Buy	338,000 +115,000	+52%	+$9.15M	0.46%	48
2013 Q2	$17.9M	Buy	+223,000	New	+$16.4M	0.38%	53

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

OrbiMed's VRTX Position: Q3 2025 in Review

OrbiMed sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 210,287 shares — an estimated $93.6M sold.

OrbiMed first reported a position in VRTX in Q2 2013 and held it in 49 quarters. The position peaked at $315M in Q3 2017. 1,521 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

OrbiMed reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
OrbiMed sold 210,287 Vertex Pharmaceuticals shares in Q3 2025, an estimated $93.6M.
OrbiMed first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 49 quarters.
OrbiMed's Vertex Pharmaceuticals position peaked at $315M in Q3 2017.
1,521 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.